二甲双胍与安慰剂对超重2型糖尿病患者身体成分的影响
该研究为哥本哈根胰岛素与二甲双胍治疗试验的子研究,双盲随机安慰剂对照,评估18个月二甲双胍联合胰岛素对比安慰剂联合胰岛素对超重2型糖尿病患者全身骨矿含量、骨密度及身体成分的影响。结果显示二甲双胍对外周骨骼BMC和BMD有小幅正面效应,并减少体重增加。
要点
- 二甲双胍对外周骨骼BMC和BMD有小幅正面效应。
- 二甲双胍组体重和脂肪质量增加少于安慰剂组。
- 效应主要来自腿部BMC和BMD增加及手臂BMC和BMD丢失。
核心结论
- 在胰岛素治疗的2型糖尿病患者中,二甲双胍对外周骨骼BMC和BMD有小幅正面效应,并减少体重增加。
研究设计与样本
- 本研究为哥本哈根胰岛素与二甲双胍治疗试验的子研究,采用双盲随机安慰剂对照设计,评估18个月二甲双胍对比安慰剂联合不同胰岛素方案对超重2型糖尿病患者全身DXA指标的影响。
主要发现
- 二甲双胍对亚全身、附肢和腿部BMC及BMD有小的正面效应(p < 0.05)。
- 校正性别、年龄、维生素D、吸烟、BMI、T2DM病程、HbA1c和胰岛素剂量后,对附肢BMC和BMD的效应持续存在(两者p < 0.05)。
- 附肢BMC和BMD变化对应二甲双胍组增加约0.7%和0.5%,安慰剂组降低0.4%和0.4%。
- 18个月内所有参与者体重、脂肪质量、FM%和瘦质量增加,LM%降低;二甲双胍组体重增加较少(亚全身体重-头部 -2.4 [-3.5, -1.4] kg,p < 0.001),FM增加较少(-1.5 [-2.3, -0.8] kg,p < 0.001),LM%降低较少(0.6 [0.2, 1.1] %,p < 0.001)。
临床怎么用
- 对于胰岛素治疗的超重2型糖尿病患者,二甲双胍可能有助于减少体重增加并对外周骨骼健康有小幅益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Some studies indicate potential beneficial effects of metformin on body composition and bone. This trial compared metformin + insulin vs placebo + insulin. Metformin treatment had a small but positive effect on bone quality in the peripheral skeleton, reduced weight gain, and resulted in a more beneficial body composition compared with placebo in insulin-treated patients with type 2 diabetes. INTRODUCTION: Glucose-lowering medications affect body composition. We assessed the long-term effects of metformin compared with placebo on whole body bone and body composition measures in patients with type 2 diabetes mellitus. METHODS: This was a sub-study of the Copenhagen Insulin and Metformin Therapy trial, which was a double-blinded randomized placebo-controlled trial assessing 18-month treatment with metformin compared with placebo, in combination with different insulin regimens in patients with type 2 diabetes mellitus (T2DM). The sub-study evaluates the effects on bone mineral content (BMC), density (BMD), and body composition from whole body dual-energy X-ray absorptiometry (DXA) scans which were assessed at baseline and after 18 months. RESULTS: Metformin had a small, but positive, (p < 0.05) effect on subtotal, appendicular, and legs BMC and BMD compared with placebo. After adjustment for sex, age, vitamin D, smoking, BMI, T2DM duration, HbA1c, and insulin dose, the effects on appendicular BMC and BMD persisted (p < 0.05 for both). The changes in appendicular BMC and BMD corresponded approximately to a 0.7% and 0.5% increase in the metformin group and 0.4% and 0.4% decrease in the placebo group, respectively. These effects were mostly driven by an increase in BMC and BMD in the legs and a loss of BMC and BMD in the arms. During 18 months, all participants increased in weight, fat mass (FM), FM%, and lean mass (LM), but decreased in LM%. The metformin group increased less in weight (subtotal weight (weight-head) - 2.4 [- 3.5, - 1.4] kg, p value < 0.001) and FM (- 1.5 [- 2.3, - 0.8] kg, p value < 0.001) and decreased less in LM% (0.6 [0.2, 1.1] %, p value < 0.001) compared with the placebo group. CONCLUSION: Metformin treatment had a small positive effect on BMC and BMD in the peripheral skeleton and reduced weight gain compared with placebo in insulin-treated patients with T2DM.
引用
- Nordklint AK, Almdal TP, Vestergaard P, et al. Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporos Int. 2021. PMID: 33594488. doi:10.1007/s00198-021-05870-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。